GlassScriptPhysician profile
Tyler Frederick Werbel
NPI 1154881589
$3,718.84
in general payments reported to CMS, 2019-2025
22 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $628 · 2023: $1,010 · 2024: $849 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,090.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.89 | 2023-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $462.26 | 2022-2025 | Dupixent |
| Genzyme Corporation | $382.40 | 2023-2025 | |
| Regeneron Pharmaceuticals, INC. | $278.86 | 2024-2025 | Libtayo |
| Ucb, INC. | $247.74 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $232.11 | 2023-2025 | Aklief |
| E.R. Squibb & Sons, L.L.C. | $179.42 | 2023-2024 | Sotyktu |
| Almirall LLC | $171.00 | 2024-2025 | Klisyri |
| Amgen INC. | $163.57 | 2022-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $158.48 | 2024-2025 | |
| Lilly USA, LLC | $138.40 | 2023-2025 | Olumiant, Ebglyss, Taltz |
| Janssen Scientific Affairs, LLC | $138.37 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.93 | 2023 | Spevigo |
| Pfizer INC. | $99.85 | 2022 | |
| Arcutis Biotherapeutics, INC. | $91.28 | 2025 | Zoryve |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $75.04 | 2024-2025 | Tremfya |
| Incyte Corporation | $72.50 | 2024-2025 | Opzelura |
| Dermavant Sciences, INC. | $70.17 | 2023 | Vtama |
| Leo Pharma INC. | $29.44 | 2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $25.02 | 2025 | |
| Journey Medical Corporation | $22.58 | 2025 | |
| Organon LLC | $13.53 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Werbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.